Akers Biosciences is up 94% premarket on increased volume on the heels of its update on strategic alternatives aimed at boosting shareholder value. Among the considerations are potential business combinations in alternative sectors, including cannabis-based industries.
Management met with a number of cannabis firms at MJBixCon in Las Vegas and has engaged Feuerstein Kulick LLP as a legal advisor as it continues its assessment of said opportunities.
Date: November 26, 2018
Source: Seeking Alpha
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.